#Pfizer

Older people, immunocompromised people and those with underlying health conditions can benefit most from additional shots.

Updated boosters could go to the “worried well” who have good insurance rather than to those at highest risk.

An NIH-sponsored study assessed boosters for adults fully vaccinated with any authorized or approved COVID-19 vaccine.

Vaccine effectiveness for children ages 5 to 11 was 91%, and serious side effects are rare.

Third dose OK’d for people over 65, those at risk for severe COVID-19 and those at high risk of exposure to the coronavirus.

Natural immunity and vaccine responses may be weaker in people with immune suppression, so they should get their second dose promptly.

A slow vaccine rollout and the emergence of new coronavirus mutations threaten progress in reducing new cases and death.

The technology used in COVID-19 vaccines may also be used to prevent other viral infections and to treat cancer and multiple sclerosis.

Pfizer-BioNTech’s coronavirus vaccine is 95% effective for preventing symptomatic illness.

The front-runner coronavirus vaccine appears to protect people from symptomatic disease.

Four vaccine candidates produced antibody and T-cell immune responses in the first stages of human clinical trials.

Over 60 drugmakers raised prices an average of 5.8% on hundreds of drugs.

At the center of the lawsuit is Teva Pharmaceutical, slated to sell a generic version of the HIV prevention pill PrEP next year.

Stop me if you’ve heard this one before.

The market for therapies to treat the condition could reach as much as $35 billion dollars over the coming years.

There are currently no approved treatments for this slow, silent liver disease that may affect up to 15 million Americans.